Exploiting tumor aneuploidy as a biomarker and therapeutic target in patients treated with immune checkpoint blockade

Since the advent of immune checkpoint blockade (ICB), there has been substantial interest in identifying biomarkers of response to facilitate treatment personalization for patients with various cancers. Tumor mutational burden (TMB) has received considerable attention as a validated biomarker of ICB response, which resulted in the 2020 FDA approval for the use of high TMB (≥10 mutations per megabase of DNA) as a tissue-agnostic biomarker for patients treated with pembrolizumab.